Atogepant (AGN-241689)

A long-term safety and tolerability extension study evaluating atogepant for the prevention of chronic or episodic migraine (NCT04686136)

Study title/design: A long-term safety and tolerability extension study evaluating atogepant for the prevention of chronic or episodic migraine (NCT04686136) Trial NCT0486136 Aim To evaluate the long-term safety and tolerability of atogepant 60 mg daily for the prevention of migraine in patients with chronic or episodic migraine Study design Phase 3, multicentre, open-label 52-week extension …

Atogepant for migraine prophylaxis in patients who failed previous oral prophylactic treatments (ELEVATE) (NCT04740827)

Study title/design: Atogepant for migraine prophylaxis in patients who failed previous oral prophylactic treatments (ELEVATE) (NCT04740827) Trial NCT04740827 Aim To evaluate the safety, tolerability and efficacy of atogepant in episodic migraine in participants who previously failed 2 to 4 classes of oral prophylactic treatments. Study design Phase 3, multicentre, double-blind, placebo-controlled, parallel-group study of atogepant …

A Phase 3, multicentre, open-label 40-week extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine (NCT03939312)

Study title/design: A Phase 3, multicentre, open-label 40-week extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine (NCT03939312) Trial NCT03939312 Aim To evaluate the safety and tolerability of atogepant 60 mg once daily for the prevention of migraine in patients with episodic …

A Phase 3, multicentre, randomised, double-blind, placebo-group study to evaluate the efficacy, safety and tolerability of atogepant for the prevention of chronic migraine (NCT03855137)

Study title/design: A Phase 3, multicentre, randomised, double-blind, placebo-group study to evaluate the efficacy, safety and tolerability of atogepant for the prevention of chronic migraine (NCT03855137) Trial NCT03855137. Recruiting, estimated primary completion 11 February, 2022; estimated study completion 11 February 2022 Aim To evaluate the efficacy, safety and tolerability of atogepant in patients with chronic …

A Phase 3, multicentre, randomised, open-label study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine (NCT03700320)

Study title/design: A Phase 3, multicentre, randomised, open-label study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine (NCT03700320) Trial NCT03700320 Aim To evaluate the safety and tolerability of atogepant 60 mg once daily for the prevention of migraine in patients with episodic migraine …

A Phase 3, multicentre, randomised double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine (ADVANCE, NCT03777059)

Study title/design: A Phase 3, multicentre, randomised double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine (ADVANCE, NCT03777059) Trial NCT03777059. Completed Aim To evaluate the safety and tolerability of atogepant 10 mg, 30 mg and 60 mg once a day …

A phase 2/3, multicentre, randomised, double-blind, placebo controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of multiple dosing regimens of oral AGN-241689 in episodic migraine prevention

Atogepant (AGN-241689) Study title/design: A phase 2b/3, multicentre, randomised, double-blind, placebo controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of multiple dosing regimens of oral AGN-241689 in episodic migraine prevention Trial NCT02848326 Aim To evaluate the safety and tolerability of AGN-241689 (atogepant) 10 mg once daily (QD), 30 mg QD, 30 mg twice daily …